Topic: acute myeloid leukemia (AML)
Roche joins Merck KGaA as pharma parter for Forty Seven's CD47-targeting antibody, which blocks a "don't eat me" signal sent out by malignant cells.
The clinical trial recorded one partial or complete response among the 48 evaluable patients, wiping 50% off Syros’ stock.
Survival in patients who received eryaspase on top of low-dose cytarabine was no longer than that for the group that just got chemotherapy alone.
Australia’s Prescient Therapeutics is getting its lead cancer program back on track, with two trials subject to FDA clinical hold cleared to resume.
Shares in Agios have fallen after a preview of ASH data that will be used to support an FDA filing for refractory acute myeloid leukemia candidate ivosidenib.
Johnson & Johnson had painted sirukumab and talacotuzumab as future blockbusters that would drive growth for years. Today, J&J abandoned those plans.
The past week brought news of discoveries in prostate cancer, Alzheimer's and dementia, and acute myeloid leukemia.
The filing positions one of 2017’s star performers on European exchanges to start trading in the U.S. and fund a phase 3 pancreatic cancer trial.
Micro cap biotech Mateon will immediately end a cancer combo with Roche’s aging Avastin in ovarian cancer after poor phase 2/3 trial results.
The past week ushered in discoveries related to high cholesterol, acute myeloid leukemia and age-related memory loss.